Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.
Moretto R, Rossini D, Murgioni S, Ciracì P, Nasca V, Germani MM, Calegari MA, Vetere G, Intini R, Taravella A, Studiale V, Boccaccio C, Passardi A, Tamburini E, Zaniboni A, Salvatore L, Pietrantonio F, Lonardi S, Masi G, Cremolini C. Moretto R, et al. Among authors: nasca v. JCO Precis Oncol. 2024 Nov;8:e2400329. doi: 10.1200/PO.24.00329. Epub 2024 Nov 7. JCO Precis Oncol. 2024. PMID: 39509668
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden.
Provenzano L, Gwee YX, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao JJ, Chia DKA, Yong WP, Tan P, So J, Kim G, Shabbir A, Ong CJ, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Provenzano L, et al. Among authors: nasca v. Ther Adv Med Oncol. 2024 Nov 4;16:17588359241289517. doi: 10.1177/17588359241289517. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39502404 Free PMC article.
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial.
Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, Conca E, Capone I, Busico A, Perrone F, Tamborini E, Sabella G, Greco G, Greco FG, Tafuto S, Procopio G, Morano F, Niger M, Maccauro M, Milione M, de Braud F, Pietrantonio F, Pusceddu S. Nasca V, et al. Eur J Cancer. 2024 Sep;209:114276. doi: 10.1016/j.ejca.2024.114276. Epub 2024 Aug 9. Eur J Cancer. 2024. PMID: 39128186 Clinical Trial.
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors.
Ghelardi F, Fucà G, Cavalli C, Shitara K, Cohen R, Ambrosini M, Maron SB, Cerantola R, Nasca V, Liberti GD, Zambelli L, Palazzo M, Salati M, Aoki Y, Kawazoe A, Cowzer D, Lonardi S, André T, Randon G, Pietrantonio F. Ghelardi F, et al. Among authors: nasca v. Dig Liver Dis. 2024 May 20:S1590-8658(24)00744-8. doi: 10.1016/j.dld.2024.05.005. Online ahead of print. Dig Liver Dis. 2024. PMID: 38772790 Free article.
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
Fanotto V, Rossini D, Casagrande M, Bergamo F, Spagnoletti A, Santini D, Antoniotti C, Cupini S, Daniel F, Nasca V, Vetere G, Zaniboni A, Borelli B, Carullo M, Conca V, Passardi A, Tamburini E, Masi G, Pella N, Cremolini C. Fanotto V, et al. Among authors: nasca v. Cancers (Basel). 2023 Nov 16;15(22):5451. doi: 10.3390/cancers15225451. Cancers (Basel). 2023. PMID: 38001711 Free PMC article.
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
Ghelardi F, Raimondi A, Morano F, Randon G, Pannone A, Guaglio M, Mazzoli G, Nasca V, Milione M, Leoncini G, Sabella G, Greco GF, Lampis BR, Galassi M, Delfanti S, Nannini M, Intini R, Baratti D, Di Bartolomeo M, Deraco M, Pietrantonio F. Ghelardi F, et al. Among authors: nasca v. Clin Colorectal Cancer. 2023 Dec;22(4):450-456.e1. doi: 10.1016/j.clcc.2023.08.005. Epub 2023 Aug 11. Clin Colorectal Cancer. 2023. PMID: 37657955
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
Ligorio F, Lobefaro R, Fucà G, Provenzano L, Zanenga L, Nasca V, Sposetti C, Salvadori G, Ficchì A, Franza A, Martinetti A, Sottotetti E, Formisano B, Depretto C, Scaperrotta G, Belfiore A, Vingiani A, Ferraris C, Pruneri G, de Braud F, Vernieri C. Ligorio F, et al. Among authors: nasca v. Int J Cancer. 2024 Jan 1;154(1):114-123. doi: 10.1002/ijc.34701. Epub 2023 Aug 24. Int J Cancer. 2024. PMID: 37615485 Free article.
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, Nasca V, Bergamo F, Conca V, Ros J, Bando H, Maddalena G, Oldani S, Prisciandaro M, Raimondi A, Schrock AB, Agnelli L, Walch H, Yoshino T, Pietrantonio F. Randon G, et al. Among authors: nasca v. Clin Cancer Res. 2024 Jan 17;30(2):436-443. doi: 10.1158/1078-0432.CCR-23-1379. Clin Cancer Res. 2024. PMID: 37610454 Free PMC article.
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.
Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, Maron SB, Cerantola R, Chao J, Fornaro L, Ferrari Bravo W, Ghelardi F, Ambrosini M, Manca P, Salati M, Kawazoe A, Zhu V, Cowzer D, Genovesi V, Lonardi S, Shitara K, André T, Pietrantonio F. Randon G, et al. Among authors: nasca v. J Immunother Cancer. 2023 Jun;11(6):e007104. doi: 10.1136/jitc-2023-007104. J Immunother Cancer. 2023. PMID: 37277193 Free PMC article.
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer.
Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, Pietrantonio F. Nasca V, et al. J Immunother Cancer. 2023 Jan;11(1):e005493. doi: 10.1136/jitc-2022-005493. J Immunother Cancer. 2023. PMID: 36593068 Free PMC article.
13 results